Nektar Therapeutics to sell Alabama facility to Ampersand
The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
ENDPOINTS NEWS1d
Nek­tar di­vests man­u­fac­tur­ing site and reagent arm for $90M
Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...
Fintel on MSN1d
Piper Sandler Initiates Coverage of Nektar Therapeutics (NKTR) with Overweight Recommendation
Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...
The Pharma Letter2d
Nektar sells its PEGylation reagent manufacturing business
Nektar said it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and reagent ...
Nektar to sell its Huntsville, Alabama facility to Ampersand Capital for $90M
Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...
Nektar Therapeutics Sells Manufacturing Facility for $90M
The latest update is out from Nektar Therapeutics ( (NKTR) ).
FiercePharma2d
Nektar pads wallet with $90M manufacturing plant sale to Ampersand
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...